Navigation Links
Potentia Pharmaceuticals Appoints Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to Scientific Advisory Board

LOUISVILLE, Ky., Nov. 11 /PRNewswire/ -- Potentia Pharmaceuticals, a privately held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today the appointments of Johanna M. Seddon, M.D. and Janet Stoltz Sunness, M.D. to its Scientific Advisory Board effective November 6, 2008.

Dr. Seddon is a world known macular degeneration specialist and pioneer in nutritional and genetic research in age-related macular degeneration, as well as an international leader in the field of ophthalmic epidemiology. For more than 20 years Dr. Seddon has directed NIH-based research on epidemiologic, biologic, and genetic biomarkers for macular degeneration and has made original contributions in these areas. Dr. Seddon is Professor of Ophthalmology at Tufts University School of Medicine and founding director of the Ophthalmic Epidemiology & Genetics Service at the New England Eye Center. She was a vice president and trustee of ARVO, and the recipient of the inaugural Maurice F. Rabb, Jr. Award from Prevent Blindness America, for dedication and contributions to prevention and treatment of age-related macular degeneration.

Dr. Sunness is an accomplished researcher in understanding how diseases cause loss of vision and has directed several National Institutes of Health-funded studies in this field. Currently, Dr. Sunness is a medical director at Hoover Services for Low Vision and Blindness at the Greater Baltimore Medical Center. Her clinical practice focuses on low vision and on retinal and macular disease. An ophthalmologist by training, Dr. Sunness is a leading world expert on geographic atrophy, the advanced dry form of age-related macular degeneration and has also pioneered new methods of measuring visual function. Dr. Sunness is also a leading world expert on how pregnancy affects the mother's eyes, both in cases of pre-existing conditions like diabetes as well as when diseases develop during pregnancy.

"We are very fortunate to have individuals of Dr. Seddon's and Dr. Sunness' standing and knowledge join Potentia's Scientific Advisory Board," said Cedric Francois, M.D., Ph.D., President and Chief Executive Officer for Potentia. "They are both extremely accomplished and held in very high regard in their fields. Their valuable insights and expertise will be of great value as we continue to develop our drug candidate, POT-4, which we believe holds great promise as a leading drug candidate in the treatment of both dry and wet AMD."

About AMD

AMD is the leading cause of blindness in the elderly of the western world and affects more than 10 million patients in the United States alone. The current standard of care for AMD relies primarily on angiogenesis inhibitors, an approach geared towards the approximately 10-15% of AMD patients with complications resulting from ocular angiogenesis (growth of new blood vessels and bleeding in the back of the eye). No drug currently on the market has been approved for the treatment of the remaining patients, who suffer from the so-called "dry" form of the disease.

About the Complement System and POT-4

Complement activation is an inflammatory process involving dozens of plasma proteins, ultimately leading to cell membrane disruption through the membrane attack complex (MAC). Activation of the complement system is an important part of the body's defensive immune response against pathogens such as bacteria and viruses. In spite of its defensive function, inappropriate or excessive complement activation can have destructive consequences if left unchecked. Over the past three years, multiple scientific publications have strongly linked variants of genes encoding components of the complement system with a predisposition toward AMD.

POT-4 binds tightly to complement component C3, preventing its participation in the complement activation cascade. As C3 is the central component of all major complement activation pathways, its inhibition effectively shuts down downstream complement activation that could otherwise lead to local inflammation, tissue damage and upregulation of angiogenic factors such as vascular endothelial growth factors (VEGF).

About Potentia

Potentia Pharmaceuticals, Inc. is an early stage biotechnology company focused on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases, with an initial emphasis on diseases of the eye such as age-related macular degeneration.

SOURCE Potentia Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. RVX-208 Exploratory Study Illustrates Early Potential for Alzheimers Disease
2. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
3. The Medicare Hospital-Acquired Conditions Initiative Will Spur Increased Patient Screening and Potentially Increased Antibiotic Use
4. Potentia Pharmaceuticals to Present ASaP Phase I Clinical Trial Data for POT-4 at the American Academy of Ophthalmology Annual Meeting
5. Innovation and Strong Therapeutic Potential Seen in Adult Stem Cells, According to Frost & Sullivan
6. Jellyfish Protein Shows Potential to Help With Memory
7. CPC of America, Inc. to Explore Strategic Alternatives; Appoints FTI Capital Advisors to Assess Potential Opportunities
8. Insmed and Premacure Cite Study Results Demonstrating Potential Effectiveness of IPLEX(TM) in Preventing Blindness in Premature Infants
9. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
10. Rosetta Genomics and the National Institute of Health (NIH) to Identify Potential MicroRNA Drug Targets for HIV
11. Self-assembling polymer arrays improve data storage potential
Post Your Comments:
(Date:10/13/2015)... SUNNYVALE, Calif. , Oct. 13, 2015  Cepheid ... the quarter ending September 30, 2015. ... financial results, total revenue for the third quarter of ... net loss per share is expected to be approximately ... financial results, non-GAAP net loss per share for the ...
(Date:10/13/2015)... Research and Markets( ) has announced ... for Bone Morphogenetic Protein Growth Factor Therapy - 16 ... --> --> Bone morphogenetic proteins ... bone after a fracture. In nature, these proteins have ... of the skeleton. There are twenty different BMPs that ...
(Date:10/13/2015)... ... October 13, 2015 , ... AxioMx ... that it has received a Phase I Small Business Innovative Research (SBIR) grant ... of General Medical Sciences (NIGMS), will fund the development of a technique to ...
(Date:10/13/2015)... 13, 2015  According to Kalorama Information, the ... $102 billion by the end of 2015. Clinical ... industry, as it is estimated that approximately 80% ... tests. In addition to diagnosing patients, clinical lab ... progression, monitor drug treatment and conditions, and determine ...
Breaking Biology Technology:
(Date:9/29/2015)... 2015 News facts: ... saving energy , Minimized design shrinks PC footprint ... Mode and embedded Fujitsu PalmSecure authentication enable enterprises to ... today shows that good things come in small packages, ... its enterprise desktop and mobile portfolio. Featuring workplace design ...
(Date:9/28/2015)... 2015 CLEAR, the leading biometric ... traveler service is coming to Austin-Bergstrom International ... a frictionless experience, serious speed and enhanced ... offers our travelers an expedited security screening ... Jim Smith , Executive Director, Austin-Bergstrom International ...
(Date:9/28/2015)... 28, 2015 The global ... USD 12.03 billion by 2020, growing at a CAGR ... as Backside Illumination (BSI) technique to improve picture quality ... period.      (Logo: , ... to reduce loss and, thus, reduce the noise interference ...
Breaking Biology News(10 mins):